Pediatric Arthritis Study of Certolizumab Pegol

PHASE3CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

March 8, 2012

Primary Completion Date

April 8, 2024

Study Completion Date

April 8, 2024

Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
DRUG

Certolizumab Pegol (CZP)

"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"

DRUG

Certolizumab Pegol (CZP)

"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"

Trial Locations (36)

10032

Ra0043 87, New York

11042

Ra0043 85, New Hyde Park

20010

Ra0043 81, Washington D.C.

27710

Ra0043 76, Durham

28203

Ra0043 74, Charlotte

44011

Ra0043 70, Avon

44109

Ra0043 78, Cleveland

44195

Ra0043 95, Cleveland

45229

Ra0043 73, Cincinnati

46202

Ra0043 75, Indianapolis

60611

Ra0043 82, Chicago

60637

Ra0043 90, Chicago

72202

Ra0043 71, Little Rock

94143

Ra0043 84, San Francisco

97227

Ra0043 89, Portland

90027-6062

Ra0043 79, Los Angeles

06106

Ra0043 83, Hartford

07601

Ra0043 80, Hackensack

07039

Ra0043 77, Livingston

43205-2694

Ra0043 86, Columbus

Unknown

RA0043 2, Buenos Aires

Ra0043 15, Curitiba

Ra0043 14, Porto Alegre

Ra0043 12, São Paulo

Ra0043 21, Calgary

Ra0043 22, Montreal

Ra0043 20, Toronto

Ra0043 60, Santiago

Ra0043 32, Mexico City

Ra0043 31, México

Ra0043 30, Monterrey

Ra0043 33, San Luis Potosí City

Ra0043 41, Moscow

Ra0043 43, Moscow

Ra0043 40, Saint Petersburg

Ra0043 42, Tolyatti

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

UCB BIOSCIENCES GmbH

INDUSTRY